Survodutide
- Category
- Weight Management & Metabolic
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
Survodutide is a dual glucagon/GLP-1 receptor agonist marketed for weight loss, blood sugar control, and liver fat reduction in MASH. Evidence is human and fairly strong, though cardiovascular benefit is speculative. The main concern is tolerability: nausea and vomiting occur several times more than placebo, driving high discontinuation; long-term cardiovascular safety is unproven. It is not FDA-approved, so supply falls outside standard channels.
Read Full recordStudied uses & evidence
Studied uses(6)
Significant Weight Loss
HighPhase 2 human trial showed about 14.9% weight loss at the highest dose versus 2.8% placebo.
Glycemic Control
High16-week human RCT in type 2 diabetes showed dose-dependent HbA1c reductions versus placebo.
MASH/Liver Fat Reduction
High48-week biopsy-confirmed human RCT showed MASH improvement in 62% of patients versus 14% placebo.
Evidence limits
- Evidence Level
- Phase 3
Survodutide has completed multiple Phase 1 and Phase 2 trials with approximately 956 participants across four key RCTs (Roux 2024 n=384, Bluher 2023 n=411, Jungnik 2022 n=125, Yazawa 2023 n=36). Phase 3 development includes the SYNCHRONIZE obesity program and the LIVERAGE MASH program. Results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD have been published. All Phase 2 trials demonstrated statistically significant efficacy for weight loss and metabolic improvement with an acceptable safety profile dominated by GI side effects.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Personal/family history of MTC
AbsoluteDual GLP-1/glucagon agonist carries thyroid C-cell tumor risk.
History of pancreatitis
HighGLP-1 class effect on pancreatitis risk. Monitor closely.
Severe gastroparesis
HighGLP-1 component slows gastric emptying.
General cautions
Pregnancy
AbsoluteInvestigational — no safety data.
Risk summary(10)
Risks = level of concern: High · Moderate · Low · Theoretical
Gastrointestinal adverse events: nausea (3.3x placebo risk), vomiting (6.64x), diarrhea (1.89x), dyspepsia (6.93x), early satiety (6.44x)
HighHigher treatment discontinuation rate due to adverse events (RR 4.53 vs placebo)
HighMild increase in heart rate (mean 2.7 bpm increase vs 0.1 bpm for placebo)
ModerateDose-dependent GI tolerability — higher doses may cause more pronounced nausea and vomiting
HighLong-term cardiovascular safety not yet established (the SYNCHRONIZE-CVOT trial, NCT06077864, completed in June 2026; no outcome results in the cited literature)
ModeratePotential for hypoglycemia when combined with insulin or sulfonylureas (theoretical risk based on GLP-1R agonist class)
ModeratePublished phase 3 obesity data extend to 76 weeks; longer-term safety remains under study.
ModerateInjection site reactions possible with subcutaneous administration
LowWeight regain upon discontinuation not yet characterized
ModerateSafety in patients with severe renal or hepatic impairment not fully established
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.